SBIR involved only since 2018, CBT Pharmaceutical was provided seed funding by its parent firm Crown Bioscience International Inc. with the spin off involved in devveloping immuno-oncology therapies and having development activities with four projects in its preclinical pipeline. Renamed Appollomics in January 2019, the firm is focused on developing innovative medicines targeting the growth and proliferation of cancer cells for which available treatments are inadequate. The firm's pipeline comprises of four development-stage assets an oral agent that specifically targets cancer metastasis, a pre-clinical candidate that targets uncontrolled growth signaling pathways, and two investigational products that restore the bodys immune system to recognize and kill cancer cells.
